Research & Development

The persistent challenge of managing generalized myasthenia gravis has long forced patients to rely on treatments that merely suppress symptoms rather than addressing the underlying immune dysfunction that causes debilitating muscle weakness. Kyverna Therapeutics and ElevateBio have recently

The fundamental shift in managing Diffuse Large B-cell Lymphoma has transitioned from standardized salvage chemotherapy to a highly personalized approach utilizing engineered immune cells that target cancer with surgical precision. For decades, the therapeutic trajectory for patients who did not

Ivan Kairatov is a seasoned expert in biopharmaceutical research and development, possessing a profound understanding of the technological shifts currently reshaping oncology. With a career dedicated to navigating the complexities of drug innovation, he has a unique perspective on how precision

The emergence of targeted therapies has fundamentally altered the trajectory of modern cancer care, yet few developments have resonated as strongly as the recent full regulatory approval of selpercatinib for adult and pediatric patients. This landmark decision by the FDA signals a profound shift in

The clinical landscape of modern oncology is undergoing a profound transformation as biotechnology firms successfully engineer specialized immune cells to target and eliminate aggressive blood cancers that have developed a resistance to conventional medical interventions. Imugene Limited, a

Modern oncology is currently witnessing a paradigm shift where the brute force of systemic chemotherapy is being replaced by sophisticated molecular delivery systems designed to spare healthy tissue. While traditional treatments often ravage the entire body to reach a localized tumor, the